The Center for Breakthrough Medicines (CBM), a contract development, and manufacturing organization (CDMO) has launched their plasmid manufacturing offering, Precision PlasmidsTM to provide phase-appropriate plasmid on-demand to accelerate the path to clinic for cell and gene therapies.

Center for Breakthrough Medicines Amplifies Viral Vector Manufacturing Capabilities by Licensing Asimov’s High-Performance GMP Suspension HEK293 Platform

Autolomous LTD, the market-leading developer of critical manufacturing management systems for Cell and Gene Therapies (CGT), today announced a license agreement with U.S.-based Center for Breakthrough Medicines (CBM) a cell and gene therapy contract development, manufacturing, and testing organization (CDMO).

End-to-End Manufacturing at a Single Site and High-throughput Vector Suite Design Will Bolster Batch Production Up to Five Times

The Center for Breakthrough Medicines (CBM), announced today the launch of their Analytical AcceleratorTM for AAV Testing to help gene therapy developers meet the quality domains of identity, safety, purity, potency, and stability required by the Food and Drug Administration (FDA) and global regulatory authorities.

Center for Breakthrough Medicines and jCyte Announce Strategic Partnership to Manufacture jCyte’s Innovative Cell Therapy for Treatment of Retinal Degenerative Diseases.